FDA Clearance And AI Advances Will Unlock Future Markets

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

14 Apr 25

Updated

05 Sep 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-36.5%

7D

-1.4%

Loading

1Y

-36.5%

7D

-1.4%

You can edit this narrative until Sep 6 10:20 AM. Then, changes will post as Updates.

Author's Valuation

AU$0.1551.3% undervalued

AnalystConsensusTarget Fair Value

Shared on 05 Sep 25

As key valuation metrics such as the Future P/E and Discount Rate for CurveBeam AI showed only marginal shifts, the analyst consensus price target was maintained at A$0.15. What's in the News Auditor PricewaterhouseCoopers LLP expressed substantial doubt about CurveBeam AI's ability to continue as a going concern in the latest annual filing.

Shared on 01 May 25

Fair value Increased 15%

Shared on 24 Apr 25

Fair value Decreased 28%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.